A Study for Exploring the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque on the Basis of Optimal Medical Therapy (Aspirin,Statins,Clopidogrel, Etc.): Stage One (NXT-ASSESS)
A Placebo Controlled, Double-blind, Randomised Trial for Assessment of the Efficacy of Naoxintong Capsules in the Treatment of Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarct on the Basis of Optimal Medical Therapy (Aspirin,Statins, Clopidogrel, Etc.)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Qian Jie
- Phone Number: +86 13601396650
- Email: qianjfw@163.com
Study Contact Backup
- Name: Runlin Gao, Prof
- Phone Number: +86 13901207581
- Email: gaorunlin@citmd.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100010
- Chinese Academy of Medical Sciences, Fuwai Hospital
-
Contact:
- Qian Jie
- Phone Number: +86 13601396650
- Email: qianjfw@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signing informed consent;
- Male or female aged 18 to 75 years old;
- AMI patients with selective PCI indication primary PCI patients are exclusive;
- No history of CABG or PCI;
Image inclusion criteria:
- CCTA at least one in-segment ≥20% and ≤70% diameter stenosis non-culprit vessel in the proximal-middle segments of RCA, LCX, LAD (the proximal and distal plaque within 5mm, same as below);
- Radiography diameter of target vessel, 2.5-4.0mm;
- Studied vessel can be evaluated with OCT and IVUS; OCT: the visual target study lesion is lipid-rich plaque with lipid arc≥100 degree and fiber cap thickness≤120µm.
Exclusion Criteria:
- Life expectancy is less than 1 year;
- Cannot implant drug stent;
- Received ≥4weeks systematic treatment of statin and other lipid-lowering drug in the 3 months before admission;
- Received ≥4 weeks systematic treatment of any traditional Chinese medicine;
- Known to have adverse reaction to ingredients of NXT capsule;
- Patients with severe heart disease that CABG or selective PCI, heart transplantationSAVR/TAVR are required during the study(12 months);
- LVEF<40%;
- Drug uncontrollable recurrent and highly symptomatic arrhythmia such as ventricular tachycaidia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia in the 3 months before ACS admission;
- Known any stroke;
- Other operations arranged during the study period (12 months);
- Uncontrollable hypertension, defined as resting systolic BP≥180mmHg;
- Clinical confirmed as statin intolerance;
- Type I diabetes or type 2 diabetes that is not well controlled;
- Moderate and severe renal dysfunction (defined as eGFR<30ml/min/1.73m2);
- Clinical confirmed liver disease or liver dysfunction (AST or ALT >3*ULN);
- Clinical confirmed infection and other hematological, metabolic gastrointestinal or endocrine dysfunction that researchers believe not suitable for enrollment;
- Known factors that may not be compliant, such as alcoholism, drug addiction, mental illness, etc.;
- Participated in other clinical research projects, or within 30 days of the last participating clinical project;
- Pregnant,breast feeding women or those plan to conceive during the study;
- History of malignant tumor.
Lesion related:
- Target segment severe calcification;
- Failed PCI in culprit vessel;
- Failed OCT screening (lipid arc/ fiber cap thickness does not match filter criteria);
- Complications during the evaluation of OCT and IVUS/VH-IVUSOCT and IVUS/VH-IVUS evaluation failed due to instruments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
|
|
Experimental: Naoxintong Capsule
|
Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plaque composition
Time Frame: 12 months
|
The change of plaque composition by virtual histology intravascular ultrasound imaging in subjects who take Naoxintong capsules and placebo in post-percutaneous coronary intervention follow-up
|
12 months
|
|
Plaque fibrous cap thickness
Time Frame: 12 months
|
The change of plaque fibrous cap thickness measured by optical coherence tomography in subjects who take Naoxintong capsules and placebo during post-percutaneous coronary intervention follow-up
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lipid arc
Time Frame: 12 months
|
The change of lipid arc measured by optical coherence tomography in subjects who take Naoxintong capsules and placebo in post-percutaneous coronary intervention follow-up
|
12 months
|
|
Percent atheroma volume
Time Frame: 12 months
|
The change of percent atheroma volume measured by intravascular ultrasound imaging in subjects who take Naoxintong capsules and placebo capsules during post-percutaneous coronary intervention follow-up
|
12 months
|
|
Total atheroma volume and low attenuation plaque volume
Time Frame: 12 months
|
Total atheroma volume and low attenuation plaque volume measured by Coronary-CTA in subjects who take Naoxintong and placebo capsules during post-percutaneous coronary intervention follow-up
|
12 months
|
|
Lipid
Time Frame: 12 months
|
The change of lipid measured by optical coherence tomography in subjects who take Naoxintong capsules
|
12 months
|
|
Platelet function
Time Frame: 12 months
|
The change of platelet function measured by optical coherence tomography in subjects who take Naoxintong capsules
|
12 months
|
|
Clinical incidents
Time Frame: 12 months
|
The number of clinical incidents in subjects who take Naoxintong capsules
|
12 months
|
|
Culprit vessel
Time Frame: 12 months
|
The change of subjects culprit vessel with optical coherence tomography;
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRFH20180010
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.